

REMARKS

With this Amendment, claims 1-17 are canceled without prejudice to later prosecution. Claims 78-125 are added and pending with entry of this Amendment.

The specification of the present application is identical to U.S. Patent Application No. 08/305,871, filed September 14, 1994, now U.S. Patent No. 5,736,142 ("the '142 patent"), with the exception that the present application claims priority to additional applications. The claims added in this Amendment are supported in U.S. Patent Application No. 08/305,871, filed September 14, 1994, now U.S. Patent No. 5,736,142 ("the '142 patent"). The '142 patent is a parent application of, and is incorporated by reference by, the present application. All support is therefore provided with reference to the '142 patent.

For example, support for new claim 78 can be found in column 6, lines 54-65 of the '142 patent, which describes recombinant DNA technology and nucleotide sequences encoding fusion proteins. The '142 patent also describes that at least one pan DR peptide of the invention can be conjugated to immunogenic peptides. *See* column 6, lines 23-30 and column 11, lines 48-59.

Description of the pan DR peptides recited in claim 78 can be found, e.g. on column 3, lines 1-19. In light of the fact that the pan DR peptides of the invention can be synthesized via recombinant DNA techniques (see above), it is clear that pan DR peptides need not include D-amino acids. *See, also*, column 10, lines 1-3 (stating that peptides of the invention "may generally comprise either L-amino acid or D-amino acids"). Indeed, claim 34 of the '142 patent is directed to pan DR peptides with the exact same amino acid sequences recited in claim 78 of the present application.

Support for "immunogenic peptide" in new claim 78 can be found, e.g., on column 6, line 56 of the '142 patent. Support for "native protein fragment or a particle" can be found, e.g., on column 4, lines 23-27 of the '142 patent.

Support for new claim 79 can be found on, e.g., column 6, lines 54-59, which states that the nucleotide sequences of the invention can be inserted into an expression vector.

Support for new claims 80-83, 88-91, 96-99, 105-108, 113-116, and 121-124 can be found on, e.g., column 10, lines 41-47, which states that one or more pan DR peptide can be conjugated to a CTL peptide. Support for new claims 80-83, 88-91, 96-99, 105-108,

0088074-1468260

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
MEH
SF 1154729 v1